Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

Elios Therapeutics Reports 24-Month Survival Data for Personalized Vaccine

Nov 21, 2019
|
staff reporter

NEW YORK – Elios Therapeutics reported 24-month survival data from a trial investigating its tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with advanced, resected melanoma.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

  2. Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors

    Premium

  3. Cartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment

    Premium

  4. Zentalis Pharmaceuticals, Tempus Partner to Explore WEE1 Inhibitor Activity in Organoid Models

  5. Celcuity Prices Upsized Public Stock Offering, Anticipates $24M in Proceeds

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.